PolarisDMD Phase 3 clinical trial for edasalonexent now recruiting in the UK

We are pleased to announce that Catabasis Pharmaceutical's PolarisDMD Phase 3 trial for edasalonexent is now recruiting in the UK at Bristol Royal Hospital for Children. Evelina London Children's Hospital, Great Ormond Street Hospital and Royal Manchester Children’s Hospital will begin recruitment soon.

  • 26-Mar-2019

POLARIS DMD is a global, placebo controlled, Phase 3 trial for edasolonexent (CAT-1004). Edasalonexent is an NF-kB inhibitor, which could provide an alterntive to steroids. Edasalonexent has been shown to preserve muscle function and substantially slow Duchenne disease progression in the MoveDMD trial.

This trial will evaluate the efficacy and safety of edasolonexent in patients with DMD, and is intended to support an application for commercial licencing of edasolonexent.

The trial is now recruiting in the UK at Bristol Royal Hospital for Children. 

Evelina London Children's Hospital, Great Ormond Street Hospital and Royal Manchester Children’s Hospital will begin recruitment soon.

For more information about this trial visit the Clinical Trial Finder.


Interested families should contact DMDtrials@catabasis.com for assistance.

 

To receive clinical trial updates directly into your inbox, Join the Hub.